Faysal Dane
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Faysal Dane has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- Perran Fulden Yumuk
Division of Medical Oncology, Department of Internal Medicine, Koç University School of Medicine, İstanbul, Turkey
7 shared publications - Tugba Basoglu
Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey
7 shared publications - Özlem Ercelep
Division of Medical Oncology, Department of Internal Medicine, Marmara University Faculty of Medicine, İstanbul 34854, Turkey
7 shared publications - Tugba Akin Telli
Department of Medical Oncology, Istanbul Florence Nightingale Hospital, Demiroğlu Bilim University, Istanbul 34381, Türkiye
5 shared publications - Abdurrahman Işıkdoğan
Department of Medical Oncology, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Turkey
4 shared publications - Mehmet Akif Ozturk
Department of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey
4 shared publications
Latest Publications
- Open Access
- 24 January 2026
- Published by Anadolu Klinigi Tip Bilimleri Dergisi in Anadolu Kliniği Tıp Bilimleri Dergisi
- Vol. 31 (1) , 42-51
Real-world practices in RAS wild-type metastatic colorectal cancer patients treated with targeted agents in the first-line a nationwide onco-colon Turkey registry
Aim: Efficacy of antiepidermal growth factor receptor (anti-EGFR) agents has been demonstrated in metastatic colorectal cancer (mCRC). Real-world evidence is especially important to detect patient findings outside of clinical trials. Therefore; we aimed to investigate the real-world data in patients with RAS wild-type mCRC. Methods: Medical records from 28 centers were collected for patients diagnosed with mCRC between January 2016 and April 2019. Patients were compared according to the first-line biological treatments as anti-EGFR group (Group A (panitumumab) and B (cetuximab)) and anti-VEGF group (Group C). Results: A total of 1064 patients with documented RAS wild-type mCRC were evaluated. Of these; 33%; 37% and 30% were treated with regimens including panitumumab; cetuximab; and anti-VEGF in the first-line; respectively. Overall response rate was 46.4%; 41.9% and 41.5% in A; B; and C groups; respectively (p = 0;170). The median OS was 26; 27; and 23 months in A; B and C group respectively (p = 0.044). The median PFS of the patients that treated with panitumumab; cetuximab and bevacizumab was 11;6; 11;0 and 9;6 months respectively (p = 0.012). ECOG performance status (PS) 0-1 and Braf wild-type status were found as independent prognostic factors in multivariate analysis for OS and only BRAF wild-type status for PFS (p
- 24 January 2026
- Published by Anadolu Klinigi Tip Bilimleri Dergisi in Anadolu Kliniği Tıp Bilimleri Dergisi
- Vol. 31 (1) , 42-51
Open AccessReal-world practices in RAS wild-type metastatic colorectal cancer patients treated with targeted agents in the first-line a nationwide onco-colon Turkey registry
Aim: Efficacy of antiepidermal growth factor receptor (anti-EGFR) agents has been demonstrated in metastatic colorectal cancer (mCRC). Real-world evidence is especially important to detect patient findings outside of clinical trials. Therefore; we aimed to investigate the real-world data in patients with RAS wild-type mCRC. Methods: Medical records from 28 centers were collected for patients diagnosed with mCRC between January 2016 and April 2019. Patients were compared according to the first-line biological treatments as anti-EGFR group (Group A (panitumumab) and B (cetuximab)) and anti-VEGF group (Group C). Results: A total of 1064 patients with documented RAS wild-type mCRC were evaluated. Of these; 33%; 37% and 30% were treated with regimens including panitumumab; cetuximab; and anti-VEGF in the first-line; respectively. Overall response rate was 46.4%; 41.9% and 41.5% in A; B; and C groups; respectively (p = 0;170). The median OS was 26; 27; and 23 months in A; B and C group respectively (p = 0.044). The median PFS of the patients that treated with panitumumab; cetuximab and bevacizumab was 11;6; 11;0 and 9;6 months respectively (p = 0.012). ECOG performance status (PS) 0-1 and Braf wild-type status were found as independent prognostic factors in multivariate analysis for OS and only BRAF wild-type status for PFS (p
- Open Access
- 7 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 467
Real-World Survival Outcomes Following Metastasectomy in RAS Wild-Type mCRC: Insights from a Multicentre National Cohort Study
Background: Metastasectomy is a cornerstone of multimodal management in metastatic colorectal cancer (mCRC), yet contemporary real-world data focusing specifically on RAS wild-type (RAS-WT) disease remain limited. We aimed to evaluate survival outcomes and prognostic factors associated with metastasectomy in patients with RAS-WT mCRC using a large national multicentre registry. Methods: This retrospective cohort study utilized data from the ONKO-KOLON Türkiye registry. A total of 1079 patients with pathologically confirmed KRAS/NRAS wild-type mCRC were identified and categorized according to receipt of metastasectomy. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method and compared with log-rank tests across multiple clinically relevant time origins, including metastatic diagnosis, initial colorectal cancer diagnosis, and time of metastasectomy. Prognostic factors within the metastasectomy cohort were assessed using univariate Cox proportional hazards models. Serum CEA and CA19-9 were analyzed after log10 transformation. Results: Among 1079 patients, 185 (17.1%) underwent metastasectomy. Patients receiving metastasectomy demonstrated significantly longer OS compared with those managed non-surgically when survival was calculated from the time of metastatic diagnosis (hazard ratio [HR] for death 0.36, 95% CI 0.27–0.47; p < 0.001), as well as improved PFS (HR for progression or death 0.39, 95% CI 0.30–0.52; p < 0.001). The survival advantage remained consistent when OS was measured from the time of initial colorectal cancer diagnosis (HR 0.37, 95% CI 0.25–0.50; p < 0.001). Median OS following metastasectomy was 43 months (95% CI 31.4–45.6). In univariate analyses within the metastasectomy cohort, higher baseline CA19-9 levels were significantly associated with inferior OS when analyzed both as a continuous variable (per log10 increase; HR 1.81, 95% CI 1.20–2.75; p = 0.005) and as a categorical variable (above vs. below threshold; HR 0.37, 95% CI 0.16–0.86; p = 0.021). Other clinicopathologic factors, including age, CEA, tumor sidedness, grade, MSI status, and metastatic burden, were not significantly associated with survival. Conclusions: In this large, real-world national cohort of RAS-WT mCRC, metastasectomy was strongly associated with prolonged survival across multiple clinically relevant time frames. Within surgically treated patients, baseline CA19-9 emerged as the most informative prognostic marker, while traditional clinicopathologic variables showed limited discriminatory value. These findings highlight the importance of careful patient selection and support further prospective studies integrating molecular and biomarker-based strategies to refine prognostication and optimize surgical decision-making in RAS-WT mCRC.
- 7 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 467
Open AccessReal-World Survival Outcomes Following Metastasectomy in RAS Wild-Type mCRC: Insights from a Multicentre National Cohort Study
Background: Metastasectomy is a cornerstone of multimodal management in metastatic colorectal cancer (mCRC), yet contemporary real-world data focusing specifically on RAS wild-type (RAS-WT) disease remain limited. We aimed to evaluate survival outcomes and prognostic factors associated with metastasectomy in patients with RAS-WT mCRC using a large national multicentre registry. Methods: This retrospective cohort study utilized data from the ONKO-KOLON Türkiye registry. A total of 1079 patients with pathologically confirmed KRAS/NRAS wild-type mCRC were identified and categorized according to receipt of metastasectomy. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method and compared with log-rank tests across multiple clinically relevant time origins, including metastatic diagnosis, initial colorectal cancer diagnosis, and time of metastasectomy. Prognostic factors within the metastasectomy cohort were assessed using univariate Cox proportional hazards models. Serum CEA and CA19-9 were analyzed after log10 transformation. Results: Among 1079 patients, 185 (17.1%) underwent metastasectomy. Patients receiving metastasectomy demonstrated significantly longer OS compared with those managed non-surgically when survival was calculated from the time of metastatic diagnosis (hazard ratio [HR] for death 0.36, 95% CI 0.27–0.47; p < 0.001), as well as improved PFS (HR for progression or death 0.39, 95% CI 0.30–0.52; p < 0.001). The survival advantage remained consistent when OS was measured from the time of initial colorectal cancer diagnosis (HR 0.37, 95% CI 0.25–0.50; p < 0.001). Median OS following metastasectomy was 43 months (95% CI 31.4–45.6). In univariate analyses within the metastasectomy cohort, higher baseline CA19-9 levels were significantly associated with inferior OS when analyzed both as a continuous variable (per log10 increase; HR 1.81, 95% CI 1.20–2.75; p = 0.005) and as a categorical variable (above vs. below threshold; HR 0.37, 95% CI 0.16–0.86; p = 0.021). Other clinicopathologic factors, including age, CEA, tumor sidedness, grade, MSI status, and metastatic burden, were not significantly associated with survival. Conclusions: In this large, real-world national cohort of RAS-WT mCRC, metastasectomy was strongly associated with prolonged survival across multiple clinically relevant time frames. Within surgically treated patients, baseline CA19-9 emerged as the most informative prognostic marker, while traditional clinicopathologic variables showed limited discriminatory value. These findings highlight the importance of careful patient selection and support further prospective studies integrating molecular and biomarker-based strategies to refine prognostication and optimize surgical decision-making in RAS-WT mCRC.
- Open Access
- 14 November 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (11) , 639
Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study
Background: Mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal tumors constitute 5% of metastatic colorectal cancer(mCRC). Immunotherapy is a new standard, but it is difficult to provide for all patients. 5-Flurouracil-based treatment with anti-EGFRs (cetuximab and panitumumab) in RAS/BRAF-wild or anti-VEGF (bevacizumab) is used in mCRC. Data is limited for the efficacy of anti-VEGF or anti-EGFRs in dMMR/MSI-H mCRC due to the small number of cases in the colorectal cancer population in trials. Aims: To evaluate prognostic factors in dMMR/MSI-H mCRC and compare progression-free survival time of patients receiving anti-VEGF and anti-EGFR combined with first-line 5FU-based therapy. Methods: Patients with metastatic dMMR/MSI-H colorectal cancer diagnosed between January 2015 and January 2023 were included in this cohort study. Progression-free survival times of patients treated with first-line therapy were compared. Prognostic factors associated with overall survival were investigated. Results: A total of 132 patients were included. Mutation rates were 35.6% (n:47) for RAS and 12.1% (n: 16) for BRAF (. Median progression-free survival (PFS) was 10.9 (95% CI: 9.2–12.6) months. Median overall survival (OS) was 44 months (95% CI: 26.23–63.03). 82 (62.1%) patients had primary tumor resection (PTR), 26 (19.7%) had PTR and metastasectomy. A total of 17 (12.8%) de novo mCRC patients had maximal cytoreductive surgery (MCS). A total of 14 (10.6%) patients had subsequent immunotherapy (IO). In multivariate analysis, RAS/BRAF mutation status, MCS, and subsequent IO are defined as prognostic factors for OS (p < 0.01, p: 0.022, and p: 0.005, respectively). No statistically significant difference (PFS, OS) was found in patients receiving first-line anti-VEGF or anti-EGFR therapy. Conclusions: dMMR/MSI-H mCRC is an entity with different tumor biology. We consider that dMMR/MSI-H mCRC patients with BRAF wild, MCS and subsequent IO have better outcomes with 1st line 5FU-based treatment with anti-VEGF/anti-EGFRs.
- 14 November 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (11) , 639
Open AccessEfficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study
Background: Mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal tumors constitute 5% of metastatic colorectal cancer(mCRC). Immunotherapy is a new standard, but it is difficult to provide for all patients. 5-Flurouracil-based treatment with anti-EGFRs (cetuximab and panitumumab) in RAS/BRAF-wild or anti-VEGF (bevacizumab) is used in mCRC. Data is limited for the efficacy of anti-VEGF or anti-EGFRs in dMMR/MSI-H mCRC due to the small number of cases in the colorectal cancer population in trials. Aims: To evaluate prognostic factors in dMMR/MSI-H mCRC and compare progression-free survival time of patients receiving anti-VEGF and anti-EGFR combined with first-line 5FU-based therapy. Methods: Patients with metastatic dMMR/MSI-H colorectal cancer diagnosed between January 2015 and January 2023 were included in this cohort study. Progression-free survival times of patients treated with first-line therapy were compared. Prognostic factors associated with overall survival were investigated. Results: A total of 132 patients were included. Mutation rates were 35.6% (n:47) for RAS and 12.1% (n: 16) for BRAF (. Median progression-free survival (PFS) was 10.9 (95% CI: 9.2–12.6) months. Median overall survival (OS) was 44 months (95% CI: 26.23–63.03). 82 (62.1%) patients had primary tumor resection (PTR), 26 (19.7%) had PTR and metastasectomy. A total of 17 (12.8%) de novo mCRC patients had maximal cytoreductive surgery (MCS). A total of 14 (10.6%) patients had subsequent immunotherapy (IO). In multivariate analysis, RAS/BRAF mutation status, MCS, and subsequent IO are defined as prognostic factors for OS (p < 0.01, p: 0.022, and p: 0.005, respectively). No statistically significant difference (PFS, OS) was found in patients receiving first-line anti-VEGF or anti-EGFR therapy. Conclusions: dMMR/MSI-H mCRC is an entity with different tumor biology. We consider that dMMR/MSI-H mCRC patients with BRAF wild, MCS and subsequent IO have better outcomes with 1st line 5FU-based treatment with anti-VEGF/anti-EGFRs.
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in Indian Journal of Cancer
- Vol. 61 (4) , 789-796
Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy
Background: We aimed to investigate the relationship between sarcopenia, which is defined by using psoas muscle index (PMI), and survival outcomes in patients with metastatic renal cell carcinoma (mRCC). Methods: This is a retrospective descriptive study of mRCC treated with first-line anti-vascular endothelial growth factor (anti-VEGF) therapy. The prognostic significance of PMI for progression-free survival (PFS) and overall survival (OS) was evaluated by univariate and multivariate analyses. Additionally, the skeletal muscle index (SMI) was calculated and correlation analysis was performed between PMI and SMI. Results: Eighty-eight patients with a median age of 60 years (interquartile range [IQR], 51–66) were included. Median PFS with first-line treatment was 6 (95% confidence interval [CI]: 2.9–9.03) months and median OS was 17 (95% CI: 10.6–23.03) months in all patients. Mean PMI was 5.71 (standard deviation [SD]: ±1.41) in women and 8.30 (SD: ±2.04) in men. Forty-seven (53.4%) patients according to PMI and 49 (55.6%) patients according to SMI were accepted as sarcopenic. The overall correlation between SMI and PMI was strong (rs = 0.73). PFS was numerically shorter in the low-PMI and low-SMI groups than the high-PMI and high-SMI groups, but it did not reach statistical significance. In univariate analyses, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score, anti-VEGF agent option, PMI, and SMI were significant prognostic factors for OS (P < 0.05 each). In multivariate analyses for OS, while IMDC score (P < 0.001) and PMI (P = 0.04) were significant independent prognostic factors according to multivariate analysis-1, IMDC score (P < 0.001) and SMI (P = 0.01) were significant independent prognostic factors according to multivariate analysis-2. Conclusions: Pretreatment PMI has a strong correlation with SMI and is an independent prognostic factor for OS in patients with mRCC.
- 1 October 2024
- Published by Wolters Kluwer Health in Indian Journal of Cancer
- Vol. 61 (4) , 789-796
Open AccessPrognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy
Background: We aimed to investigate the relationship between sarcopenia, which is defined by using psoas muscle index (PMI), and survival outcomes in patients with metastatic renal cell carcinoma (mRCC). Methods: This is a retrospective descriptive study of mRCC treated with first-line anti-vascular endothelial growth factor (anti-VEGF) therapy. The prognostic significance of PMI for progression-free survival (PFS) and overall survival (OS) was evaluated by univariate and multivariate analyses. Additionally, the skeletal muscle index (SMI) was calculated and correlation analysis was performed between PMI and SMI. Results: Eighty-eight patients with a median age of 60 years (interquartile range [IQR], 51–66) were included. Median PFS with first-line treatment was 6 (95% confidence interval [CI]: 2.9–9.03) months and median OS was 17 (95% CI: 10.6–23.03) months in all patients. Mean PMI was 5.71 (standard deviation [SD]: ±1.41) in women and 8.30 (SD: ±2.04) in men. Forty-seven (53.4%) patients according to PMI and 49 (55.6%) patients according to SMI were accepted as sarcopenic. The overall correlation between SMI and PMI was strong (rs = 0.73). PFS was numerically shorter in the low-PMI and low-SMI groups than the high-PMI and high-SMI groups, but it did not reach statistical significance. In univariate analyses, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score, anti-VEGF agent option, PMI, and SMI were significant prognostic factors for OS (P < 0.05 each). In multivariate analyses for OS, while IMDC score (P < 0.001) and PMI (P = 0.04) were significant independent prognostic factors according to multivariate analysis-1, IMDC score (P < 0.001) and SMI (P = 0.01) were significant independent prognostic factors according to multivariate analysis-2. Conclusions: Pretreatment PMI has a strong correlation with SMI and is an independent prognostic factor for OS in patients with mRCC.
- Open Access
- 1 January 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (6) , 1205-1214
Evaluating the performance of the Mskcc gastric cancer survıval calculator in the Turkısh population
Bacground/Aim: The MSKCC(Memorial Sloan Kettering Cancer Center) nomogram was developed to predict survivorship in gastric cancer patients undergoing R0 resection. This study aimed to evaluate the predictive power of this nomogram in the Turkish patient population. Materials and Methods: Gastric cancer patients over 18 years of age who were admitted to our clinic between 2000 and 2019 and underwent primary curative surgery and R0 resection were included in the study. The 5-year and 9-year overall survival rates of 489 patients were analyzed. Real-life survival rates and those calculated with the MSKCC tool were compared in all patients and subgroups. The relationship between variables and survival were analyzed.Results:The 5-year median overall survival observed in all patients was 51.7%, while the 5-year median overall survival calculated with the MSKCC mediator was 48.5%. The difference between expected and observed survival rates were calculated as 3.2%. The ratios were similar and there was no statistically significant difference (p:0.31).The 9-year median overall survival observed in all patients was 41.4%, while the 5-year median overall survival calculated with the MSKCC mediator was 41%. The difference between expected and observed survival rates was calculated as 0.4%. The ratios were similar and there was no statistically significant difference (p:0.9).Conclusion: We found that 5-year and 9-year survival rates estimated by MSKCC toll were correlated with 5-year and 9-year survival rates in real-life data. We believe that the use of the MSKCC prognostic tool in clinical practice should be expanded.
- 1 January 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (6) , 1205-1214
Open AccessEvaluating the performance of the Mskcc gastric cancer survıval calculator in the Turkısh population
Bacground/Aim: The MSKCC(Memorial Sloan Kettering Cancer Center) nomogram was developed to predict survivorship in gastric cancer patients undergoing R0 resection. This study aimed to evaluate the predictive power of this nomogram in the Turkish patient population. Materials and Methods: Gastric cancer patients over 18 years of age who were admitted to our clinic between 2000 and 2019 and underwent primary curative surgery and R0 resection were included in the study. The 5-year and 9-year overall survival rates of 489 patients were analyzed. Real-life survival rates and those calculated with the MSKCC tool were compared in all patients and subgroups. The relationship between variables and survival were analyzed.Results:The 5-year median overall survival observed in all patients was 51.7%, while the 5-year median overall survival calculated with the MSKCC mediator was 48.5%. The difference between expected and observed survival rates were calculated as 3.2%. The ratios were similar and there was no statistically significant difference (p:0.31).The 9-year median overall survival observed in all patients was 41.4%, while the 5-year median overall survival calculated with the MSKCC mediator was 41%. The difference between expected and observed survival rates was calculated as 0.4%. The ratios were similar and there was no statistically significant difference (p:0.9).Conclusion: We found that 5-year and 9-year survival rates estimated by MSKCC toll were correlated with 5-year and 9-year survival rates in real-life data. We believe that the use of the MSKCC prognostic tool in clinical practice should be expanded.
- 13 June 2022
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (22) , 2425-2439
Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy
Objective: The aim of this study was to investigate quality-of-life (QoL) in breast cancer (BC) patients treated with adjuvant endocrine therapy (AET). Methods: We designed a cross-sectional study ... Plain language summary Breast cancer (BC) remains the most common cancer among women worldwide. Hormone receptor-positive (estrogen receptor- and/or progesterone receptor-positive) BC represents 70...
- 13 June 2022
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (22) , 2425-2439
Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy
Objective: The aim of this study was to investigate quality-of-life (QoL) in breast cancer (BC) patients treated with adjuvant endocrine therapy (AET). Methods: We designed a cross-sectional study ... Plain language summary Breast cancer (BC) remains the most common cancer among women worldwide. Hormone receptor-positive (estrogen receptor- and/or progesterone receptor-positive) BC represents 70...
- Open Access
- 14 March 2022
- Published by Galenos Yayinevi in Namık Kemal Tıp Dergisi
- Vol. 10 (1) , 74-79
The Prognostic and Predictive Value of DR-70 Immunoassay, A Novel Fibrin-Associated Biomarker, in Patients with Advanced Gastrointestinal Cancers
- 14 March 2022
- Published by Galenos Yayinevi in Namık Kemal Tıp Dergisi
- Vol. 10 (1) , 74-79
Open AccessThe Prognostic and Predictive Value of DR-70 Immunoassay, A Novel Fibrin-Associated Biomarker, in Patients with Advanced Gastrointestinal Cancers
- Open Access
- 23 November 2021
- Published by AVES YAYINCILIK A.Ş. in Balkan Medical Journal
- Vol. 39 (1) , 12-20
Prognostic Value of Tissue-Resident Memory T Cells and Tumor Microenvironmental Features in Resected Pancreatic Adenocarcinoma
Pancreatic ductal adenocarcinoma differs from other solid tumors with its unique immunosuppressive microenvironment and non-immunogenic feature. There are not many studies in the literature investigating the effect of these features on prognosis. To investigate the prognostic value of tissue-resident memory T cells, tumor microenvironment features, and tumor-associated immune cells in resected pancreatic ductal adenocarcinomas. Retrospective cross-sectional study. Of 138 patients diagnosed with pancreatic ductal adenocarcinoma between 2011 and 2018, 81 were included in the study. Specimens from operated patients were reassessed separately as peritumoral and intratumoral areas for tissue resident memory cells and tumor microenvironmental elements (tumor infiltrating lymphocytes, tumor stroma, CD204+ macrophages, PDL1+ immune cells). Disease-free survival and overall survival were defined from the date of operation to the date of recurrence and the date of first diagnosis to the date of death, respectively. If the patient was alive, the last visit date was taken into account. The median age at diagnosis was 63 (range: 40-78). The median follow-up period was 18.9 months (range: 1.4-80.4 months). Median overall survival was 23.7 months (1.4-80.4 months) and median disease-free survival was 10.8 months (1.4-74.4 months). Patients with higher intra-tumoral tissue-resident memory cell counts had a longer survival trend than those having lower values (25.6 months vs. 18 months, respectively, P = .84). According to microenvironmental evaluations, lower stromal score (defined as stroma having less desmoplasia and rich in cells) and presence of peritumoral Crohn’s-like inflammatory response were associated with higher survival (29.2 months vs. 19.7 months for low vs. high stromal scores, respectively, P = .16 and 30.2 months vs. 18.1 months for the presence of Crohn’s-like inflammatory response P = .13). Decreased survival was observed in tumors with increased CD204+ tumor-associated macrophages which were immunosuppressive elements of the microenvironment (12 months vs. 26.3 months for intra-tumoral assessment, P = .29). Tissue-resident memory T cells and other microenvironmental features may be prognostic in resectable pancreatic ductal adenocarcinomas. Further studies with larger cohorts are needed for validation.
- 23 November 2021
- Published by AVES YAYINCILIK A.Ş. in Balkan Medical Journal
- Vol. 39 (1) , 12-20
Open AccessPrognostic Value of Tissue-Resident Memory T Cells and Tumor Microenvironmental Features in Resected Pancreatic Adenocarcinoma
Pancreatic ductal adenocarcinoma differs from other solid tumors with its unique immunosuppressive microenvironment and non-immunogenic feature. There are not many studies in the literature investigating the effect of these features on prognosis. To investigate the prognostic value of tissue-resident memory T cells, tumor microenvironment features, and tumor-associated immune cells in resected pancreatic ductal adenocarcinomas. Retrospective cross-sectional study. Of 138 patients diagnosed with pancreatic ductal adenocarcinoma between 2011 and 2018, 81 were included in the study. Specimens from operated patients were reassessed separately as peritumoral and intratumoral areas for tissue resident memory cells and tumor microenvironmental elements (tumor infiltrating lymphocytes, tumor stroma, CD204+ macrophages, PDL1+ immune cells). Disease-free survival and overall survival were defined from the date of operation to the date of recurrence and the date of first diagnosis to the date of death, respectively. If the patient was alive, the last visit date was taken into account. The median age at diagnosis was 63 (range: 40-78). The median follow-up period was 18.9 months (range: 1.4-80.4 months). Median overall survival was 23.7 months (1.4-80.4 months) and median disease-free survival was 10.8 months (1.4-74.4 months). Patients with higher intra-tumoral tissue-resident memory cell counts had a longer survival trend than those having lower values (25.6 months vs. 18 months, respectively, P = .84). According to microenvironmental evaluations, lower stromal score (defined as stroma having less desmoplasia and rich in cells) and presence of peritumoral Crohn’s-like inflammatory response were associated with higher survival (29.2 months vs. 19.7 months for low vs. high stromal scores, respectively, P = .16 and 30.2 months vs. 18.1 months for the presence of Crohn’s-like inflammatory response P = .13). Decreased survival was observed in tumors with increased CD204+ tumor-associated macrophages which were immunosuppressive elements of the microenvironment (12 months vs. 26.3 months for intra-tumoral assessment, P = .29). Tissue-resident memory T cells and other microenvironmental features may be prognostic in resectable pancreatic ductal adenocarcinomas. Further studies with larger cohorts are needed for validation.
- Open Access
- 30 March 2020
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-7
Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study
Background: Combination of gemcitabine and nab-paclitaxel has superior clinical efficacy than gemcitabine alone. Nevertheless, health-related quality of life. (QoL) associated with this combination therapy when administered at first-line in advanced pancreatic adenocarcinoma is unknown. Methods: A total of 125 patients were randomized to combination therapy (1000 mg/m2 gemcitabine + 125 mg/m2 nab-paclitaxel) and single-agent gemcitabine (1000 mg/m2) arms to take treatment weekly for 7 of 8 weeks, and following 3 of 4 weeks, until progression or severe toxicity. Primary endpoints were three-months of definitive deterioration free percent of patients, and QoL. Results: Overall QoL analyses showed that 34 and 58.3% of cases in gemcitabine and gemcitabine+nab-P arms had no deterioration in 3rd month QoL scores (p = 0.018). These proportions were 27.3 and 36.6% in 6th month assessments, respectively (p = 0.357). Median overall survivals in combination and single-agent arms were 9.92 months and 5.95 months, respectively (HR: 0.64, 95% CI: 0.42–0.86, p = 0.038). Median progression free survivals in these treatment arms were 6.28 and 3.22 months, respectively (HR: 0.58, 95% CI: 0.39–0.87, p = 0.008). Median time-to-deterioration were 5.36 vs 3.68 months, and objective response rates were 37.1% vs 23.7% (p = 0.009), respectively in combination and single-agent arms. Conclusions: Combination therapy with gemcitabine + nab-paclitaxel had better overall and progression-free survival than gemcitabine alone. Also, combination therapy showed increased response rate without toxicity or deteriorated QoL. Combination treatment with gemcitabine and nab-paclitaxel may provide significant benefit for advanced pancreatic cancer. Trial registration: This study has been registered in ClinicalTrials.gov as NCT03807999 on January 8, 2019 (retrospectively registered).
- 30 March 2020
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-7
Open AccessQuality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study
Background: Combination of gemcitabine and nab-paclitaxel has superior clinical efficacy than gemcitabine alone. Nevertheless, health-related quality of life. (QoL) associated with this combination therapy when administered at first-line in advanced pancreatic adenocarcinoma is unknown. Methods: A total of 125 patients were randomized to combination therapy (1000 mg/m2 gemcitabine + 125 mg/m2 nab-paclitaxel) and single-agent gemcitabine (1000 mg/m2) arms to take treatment weekly for 7 of 8 weeks, and following 3 of 4 weeks, until progression or severe toxicity. Primary endpoints were three-months of definitive deterioration free percent of patients, and QoL. Results: Overall QoL analyses showed that 34 and 58.3% of cases in gemcitabine and gemcitabine+nab-P arms had no deterioration in 3rd month QoL scores (p = 0.018). These proportions were 27.3 and 36.6% in 6th month assessments, respectively (p = 0.357). Median overall survivals in combination and single-agent arms were 9.92 months and 5.95 months, respectively (HR: 0.64, 95% CI: 0.42–0.86, p = 0.038). Median progression free survivals in these treatment arms were 6.28 and 3.22 months, respectively (HR: 0.58, 95% CI: 0.39–0.87, p = 0.008). Median time-to-deterioration were 5.36 vs 3.68 months, and objective response rates were 37.1% vs 23.7% (p = 0.009), respectively in combination and single-agent arms. Conclusions: Combination therapy with gemcitabine + nab-paclitaxel had better overall and progression-free survival than gemcitabine alone. Also, combination therapy showed increased response rate without toxicity or deteriorated QoL. Combination treatment with gemcitabine and nab-paclitaxel may provide significant benefit for advanced pancreatic cancer. Trial registration: This study has been registered in ClinicalTrials.gov as NCT03807999 on January 8, 2019 (retrospectively registered).
- Open Access
Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study
Objectives Regorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies in two randomised, phase III trials, but has not been evaluated in Turkey. REGARD evaluated the safety and efficacy of regorafenib in Turkish patients with treatment-refractory mCRC. Design Open-label, single-arm, phase IIIb study conducted between July 2013 and April 2015. Setting 11 tertiary centres in Turkey. Participants Eligible patients were adults with mCRC who had disease progression within 3 months after receiving their last dose of approved standard therapies and who had an Eastern Cooperative Oncology Group performance status ≤1. Patients were excluded if they had previously received regorafenib. Of 139 patients screened, 100 were treated and completed the study, and all 100 were analysed. Fifty-eight per cent were male. Interventions Patients received oral regorafenib, 160 mg once daily, for the first 3 weeks of each 4-week cycle until disease progression, death or unacceptable toxicity. Primary and secondary outcome measures The primary endpoint was safety, assessed by incidence of treatment-emergent adverse events (TEAEs). Progression-free survival (PFS) per investigator was the primary efficacy endpoint. There were no secondary endpoints. Results The median treatment duration was 2.5 months (range 0.1 to 20.6). Ninety-six per cent of patients had at least one TEAE and 77% had a grade ≥3 TEAE. The most common grade ≥3 regorafenib-related TEAEs were hypophosphataemia (11%), fatigue (8%), hyperbilirubinaemia (6%), hand–foot skin reaction (5%), hypertension (5%), anorexia (5%) and increased alanine aminotransferase (5%). TEAEs led to dose reduction in 30% of patients. Regorafenib-related TEAEs led to treatment discontinuation in 17% of patients. Median PFS was 3.1 months (95% CI 2.9 to 3.8). Conclusion The regorafenib safety profile and PFS in REGARD were consistent with the results of previous trials of regorafenib in mCRC. Regorafenib is an option for patients in Turkey with treatment-refractory mCRC. Trial registration number NCT01853319, ClinicalTrials.gov.
Open AccessSafety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study
Objectives Regorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies in two randomised, phase III trials, but has not been evaluated in Turkey. REGARD evaluated the safety and efficacy of regorafenib in Turkish patients with treatment-refractory mCRC. Design Open-label, single-arm, phase IIIb study conducted between July 2013 and April 2015. Setting 11 tertiary centres in Turkey. Participants Eligible patients were adults with mCRC who had disease progression within 3 months after receiving their last dose of approved standard therapies and who had an Eastern Cooperative Oncology Group performance status ≤1. Patients were excluded if they had previously received regorafenib. Of 139 patients screened, 100 were treated and completed the study, and all 100 were analysed. Fifty-eight per cent were male. Interventions Patients received oral regorafenib, 160 mg once daily, for the first 3 weeks of each 4-week cycle until disease progression, death or unacceptable toxicity. Primary and secondary outcome measures The primary endpoint was safety, assessed by incidence of treatment-emergent adverse events (TEAEs). Progression-free survival (PFS) per investigator was the primary efficacy endpoint. There were no secondary endpoints. Results The median treatment duration was 2.5 months (range 0.1 to 20.6). Ninety-six per cent of patients had at least one TEAE and 77% had a grade ≥3 TEAE. The most common grade ≥3 regorafenib-related TEAEs were hypophosphataemia (11%), fatigue (8%), hyperbilirubinaemia (6%), hand–foot skin reaction (5%), hypertension (5%), anorexia (5%) and increased alanine aminotransferase (5%). TEAEs led to dose reduction in 30% of patients. Regorafenib-related TEAEs led to treatment discontinuation in 17% of patients. Median PFS was 3.1 months (95% CI 2.9 to 3.8). Conclusion The regorafenib safety profile and PFS in REGARD were consistent with the results of previous trials of regorafenib in mCRC. Regorafenib is an option for patients in Turkey with treatment-refractory mCRC. Trial registration number NCT01853319, ClinicalTrials.gov.